EpiCept to Report Third Quarter 2012 Operating and Financial Results on November 14, 2012
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
announced today that it will host a conference call on Wednesday,
November 14, 2012 at 9:00 a.m. Eastern time to discuss recent events and
the third quarter 2012 operating and financial results. The call will
follow the release of these financial results earlier in the day at
12:01 a.m. Eastern time.
To participate in the live call and be able to participate in the
question and answer session, please dial from the U.S. and Canada (877)
809-8594 or from international locations (706) 758-9407 (please
reference access code 70213691) prior to the start of the conference.
The conference call will also be broadcast live in listen-only mode on
the Internet and may be accessed at www.epicept.com.
The webcast will be archived for 90 days.
A telephone replay of the call will be available for seven days by
dialing from the U.S. and Canada (855) 859-2056 or from international
locations (404) 537-3406 (please reference reservation number 70213691).
About EpiCept Corporation
EpiCept is focused on the development and commercialization of
pharmaceutical products for the treatment of pain and cancer. The
Company's pain portfolio includes AmiKet™, a prescription topical
analgesic cream in late-stage clinical development designed to provide
effective long-term relief of pain associated with peripheral
neuropathies. The Company's product Ceplene®, when used
concomitantly with low-dose IL-2 is intended as remission maintenance
therapy in the treatment of AML for adult patients who are in their
first complete remission. The Company sold all of its rights to Ceplene®
in Europe and certain Pacific Rim countries and a portion of its
remaining Ceplene® inventory to Meda AB in June 2012. Ceplene®
is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept
has retained its rights to Ceplene® in all other countries,
including countries in North and South America. The Company has other
oncology drug candidates in clinical development that were discovered
using in-house technology and have been shown to act as vascular
disruption agents in a variety of solid tumors. For more information,
visit the EpiCept website at: www.epicept.com
Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals, targets,
future development and are otherwise not statements of historical fact.
These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or
developments to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Factors that may cause actual results or developments to
differ materially include: the risks associated with the adequacy of our
existing cash resources and our ability to continue as a going concern,
the risks associated with our ability to continue to meet our
obligations under our existing debt agreements, the risk that Azixa®
will not receive regulatory approval or achieve significant commercial
success, the risk that clinical trials for AmiKet™ or crolibulinTM will
not be successful, the risk that AmiKet™ or crolibulinTM will
not receive regulatory approval or achieve significant commercial
success, the risk that we will not be able to find a partner to help
conduct the Phase III trials for AmiKet™ on attractive terms, a timely
basis or at all, the risk that Ceplene® will not receive
regulatory approval or marketing authorization in the United States or
Canada, the risk that Ceplene® will not achieve significant
commercial success, the risk that our other product candidates that
appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials, the risk that we will not obtain approval to market any
of our product candidates, the risks associated with dependence upon key
personnel, the risks associated with reliance on collaborative partners
and others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly competitive
nature of our business; risks associated with litigation; and risks
associated with our ability to protect our intellectual property. These
factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and
other filings with the U.S. Securities and Exchange Commission. You are
urged to carefully review and consider the disclosures found in our
filings which are available at www.sec.gov
or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to inaccurate
assumptions, unknown risks or uncertainties or other risk factors.
EPCT-GEN
EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein
Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
LHA
Kim
Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce
Voss, 310-691-7100
bvoss@lhai.com
Source: EpiCept Corporation
News Provided by Acquire Media
Close window | Back to top
